評論
打印
On Monday, a new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR in humans.
周一，新論文發現在人類身上使用革命性基因編輯工具“CRISPR”有可能存在障礙。
The news sent the stocks of all three major CRISPR biotech firms tumbling in premarket trading.
該新聞出現使得三大“CRISPR”生物科技公司股價在盤前交易中暴跌。
They declined by as much as 11.9 percent.
他們的股價下跌了11.9%之多。
In recent years, CRISPR has been credited with the potential power to correct any number of devastating diseases.
近些年，“CRISPR”一直被認為擁有治愈各種可怕的疾病的潛在力量。
Researchers have used it to cure mice of deadly genetic conditions like hemophilia B, Lou Gehrig's disease, and Huntington's disease.
研究者使用該技術治愈了老鼠的致命性基因疾病，如乙型血友病，盧伽雷病和亨廷頓病。
In the U.S., the first human CRISPR trials are slated to begin this year.
美國首例人類“CRISPR”試驗計劃在今年開始進行。
譯文屬可可英語原創，未經允許，不得轉載。
